文献速递其他结缔组织病

进行性肺纤维化及其对系统性硬化症相关间质性肺疾病生存的影响

Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

在系统性硬化症相关间质性肺疾病(SSc-ILD)新发病例队列中,38.8%(n=180)在ILD诊断后12个月内发生进行性肺纤维化(PPF)。PPF的确定因素包括年龄较大、弥漫性皮肤型SSc及SSc特异性抗体。PPF显著影响生存(HR 2.66,95%CI 1.59-4.41,P<0.001)。

要点

  • 38.8%(n=180)的新发SSc-ILD患者在诊断后12个月内发生PPF。
  • 年龄较大、dcSSc、抗Scl-70抗体与PPF风险升高相关,抗着丝点抗体与风险降低相关。
  • PPF显著影响生存,HR为2.66(95%CI 1.59-4.41,P<0.001)。

核心结论

  • PPF发生于约三分之一的新发SSc-ILD队列中,其发生与死亡率显著相关,提示该高风险群体可能适合更早引入免疫抑制和/或抗纤维化治疗。

研究设计与样本

  • 研究为新发SSc-ILD队列,新发ILD定义为胸部HRCT扫描新出现特征性纤维化改变。
  • PPF依据2022年美国胸科学会定义。
  • PPF的确定因素使用广义估计方程分析,对生存的影响使用加速失效时间回归模型分析。

主要发现

  • 38.8%(n=180)的新发SSc-ILD病例在ILD诊断后12个月内发生PPF。
  • 年龄较大与PPF相关(OR 1.02,95%CI 1.00-1.03,P=0.011)。
  • dcSSc与PPF相关(OR 1.54,95%CI 1.06-2.25,P=0.024)。
  • 抗着丝点抗体与PPF相关(OR 0.51,95%CI 0.29-0.91,P=0.021),抗Scl-70抗体与PPF相关(OR 1.46,95%CI 1.01-2.09,P=0.043)。
  • CRP升高与PPF在数值上相关但未达统计学显著(OR 1.29,95%CI 0.99-1.68,P=0.064),胃食管反流病(OR 1.18,95%CI 0.57-2.42,P=0.658)和吞咽困难(OR 1.17,95%CI 0.57-2.40,P=0.664)亦然。

临床怎么用

  • 作者认为,PPF发生与死亡率显著相关,提示该高风险群体可能适合更早引入免疫抑制和/或抗纤维化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the frequency of progressive pulmonary fibrosis (PPF) in an incident cohort of systemic sclerosis (SSc)-related interstitial lung disease (ILD) and its impact on survival. METHODS: Incident ILD was defined as the new development of characteristic fibrotic changes on chest HRCT scan. PPF was defined as per the 2022 American Thoracic Society. Determinants of PPF were identified using generalised estimating equations. Impact on survival was analysed using accelerated failure time regression modelling. RESULTS: Of our incident SSc-ILD cases, 38.8% (n = 180) experienced PPF within a 12-month period after ILD diagnosis. Determinants of PPF included older age (OR 1.02, 95%CI 1.00-1.03, P = 0.011), dcSSc (OR 1.54, 95% CI 1.06-2.25, P = 0.024) and SSc-specific antibodies (anticentomere antibody OR 0.51, 95%CI 0.29-0.91, P = 0.021 and anti-Scl-70 antibody OR 1.46, 95%CI 1.01-2.09, P = 0.043). Raised CRP was numerically associated with PPF but did not reach statistical significance (OR 1.29, 95%CI 0.99-1.68, P = 0.064) nor did GORD or dysphagia (OR 1.18, 95%CI 0.57-2.42, P = 0.658 and OR 1.17, 95%CI 0.57-2.40, P = 0.664, respectively). The presence of PPF significantly impacted survival in SSc-ILD (hazard ratio 2.66, 95%CI 1.59-4.41, P < 0.001). CONCLUSIONS: PPF occurred in a third of our incident SSc-ILD cohort; however, its occurrence was significantly associated with mortality indicating an at-risk group who may be suitable for earlier introduction of immunosuppressive and/or antifibrotic therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Morrisroe K, Hansen D, Stevens W, et al. Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2024. PMID: 37725359. doi:10.1093/rheumatology/kead491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。